Polpharma Signs an Exclusive Worldwide Commercialization Agreement with Sandoz for Proposed Biosimilar Natalizumab to Treat Relapsing-Remitting Multiple Sclerosis

Polpharma Signs an Exclusive Worldwide Commercialization Agreement with Sandoz for Proposed Biosimilar Natalizumab to Treat Relapsing-Remitting Multiple Sclerosis

Shots:

  • Sandoz to get WW rights to distribute & commercialize proposed biosimilar natalizumab in all markets following its approval. Polpharma Biologics will be responsible for development, manufacturing and supply of proposed biosimilar natalizumab
  • The focus of the agreement is to expand Novartis/Sandoz’s portfolio across small molecules, complex generics, biosimilars, and innovator therapies with the addition of proposed biosimilar natalizumab enabling patients to access patented and off-patent therapies
  • Natalizumab is a mAb targeting adhesion molecule α4-integrin, the first-in-class therapy for the treatment of MS and is the fifth proposed biosimilar in-licensed by Sandoz in 9 months  

Click here to­ read full press release/ article | Ref: Novartis | Image: Behance